Levodopa-induced dyskinesia: do current clinical trials hold hope for future treatment?

References

• Hely MA, Morris JG, Reid WG, et al. Sydney multicenter study of Parkinson’s disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord. 2005 Feb;20(2):190–199.
   PubMed Web of Science ®Google Scholar
• Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2018 Aug;33(8):1248–1266.
   PubMed Web of Science ®Google Scholar
• Huot P, Fox SH, Brotchie JM. The serotonergic system in Parkinson’s disease. Prog Neurobiol. 2011 Aug 22;95(2):163–212.
   PubMed Web of Science ®Google Scholar
• Hamik A, Oksenberg D, Fischette C, et al. Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites. Biol Psychiatry. 1990 Jul 15;28(2):99–109. doi: 10.1016/0006-3223(90)90627-E
   PubMed Web of Science ®Google Scholar
• Colpaert FC, Tarayre JP, Koek W, et al. Large-amplitude 5-HT1A receptor activation: a new mechanism of profound, central analgesia. Neuropharmacology. 2002 Nov;43(6):945–58.
   PubMed Web of Science ®Google Scholar
• Martin GR. Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine. Cephalalgia. 1997 Oct;17(Suppl 18):4–14. doi: 10.1177/0333102497017S1802
   PubMedGoogle Scholar
• Zanos P, Moaddel R, Morris PJ, et al. Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol Rev. 2018 Jul;70(3):621–660.
   PubMed Web of Science ®Google Scholar
• Vecsei L, Szalardy L, Fulop F, et al. Kynurenines in the CNS: recent advances and new questions. Nat Rev Drug Discov. 2013 Jan;12(1):64–82.
   PubMed Web of Science ®Google Scholar
• Wu N, Song L, Yang XX, et al. Effects of Chinese herbal medicine Tianqi Pingchan Granule on G protein-coupled receptor kinase 6 involved in the prevention of levodopa-induced dyskinesia in rats with Parkinson disease. J Chin Integr Med. 2012 Sep;10(9):1018–1024.
   PubMedGoogle Scholar
• Waters S, Sonesson C, Svensson P, et al. Preclinical pharmacology of [2-(3-fluoro-5-methanesulfonyl-phenoxy)Ethyl](Propyl)amine (IRL790), a novel dopamine transmission modulator for the Treatment of Motor and psychiatric complications in Parkinson disease. J Pharmacol Exp Ther. 2020 Jul;374(1):113–125.
   PubMed Web of Science ®Google Scholar
• Matloka M, Janowska S, Pankiewicz P, et al. A PDE10A inhibitor CPL500036 is a novel agent modulating striatal function devoid of most neuroleptic side-effects. Front Pharmacol. 2022;13:999685. doi: 10.3389/fphar.2022.999685
   PubMed Web of Science ®Google Scholar
• Li P, Zheng H, Zhao J, et al. Discovery of potent and selective inhibitors of phosphodiesterase 1 for the treatment of cognitive impairment associated with neurodegenerative and neuropsychiatric diseases. J Med Chem. 2016 Feb 11;59(3):1149–64. doi: 10.1021/acs.jmedchem.5b01751
   PubMed Web of Science ®Google Scholar
• Cenci MA, Skovgard K, Odin P. Non-dopaminergic approaches to the treatment of motor complications in Parkinson’s disease. Neuropharmacology. 2022 Jun 1;210:109027. doi: 10.1016/j.neuropharm.2022.109027
   PubMed Web of Science ®Google Scholar
• Al-Kassmy J, Sun C, Huot P. 5-HT(1A) agonists for levodopa-induced dyskinesia in Parkinson’s disease. Neurodegener Dis Manag. 2023 Apr;13(2):101–112. doi: 10.2217/nmt-2022-0039
   PubMed Web of Science ®Google Scholar
• Jackson MJ, Al-Barghouthy G, Pearce RK, et al. Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets. Pharmacol Biochem Behav. 2004 Nov;79(3):391–400.
   PubMed Web of Science ®Google Scholar
• Kannari K, Kurahashi K, Tomiyama M, et al. Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson’s disease. No To Shinkei. 2002 Feb;54(2):133–137.
   PubMedGoogle Scholar
• Iderberg H, McCreary AC, Varney MA, et al. NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: behavioral and neurochemical profile in rat. Exp Neurol. 2015 Sep;271:335–50.
   PubMed Web of Science ®Google Scholar
• Depoortere R, Johnston TH, Fox SH, et al. The selective 5-HT(1A) receptor agonist, NLX-112, exerts anti-dyskinetic effects in MPTP-treated macaques. Parkinsonism Related Disord. 2020 Sep;78:151–157. doi: 10.1016/j.parkreldis.2020.08.009
   PubMed Web of Science ®Google Scholar
• Fisher R, Hikima A, Morris R, et al. The selective 5-HT(1A) receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets. Neuropharmacology. 2020 May 1;167:107997. doi: 10.1016/j.neuropharm.2020.107997
   PubMed Web of Science ®Google Scholar
• Sherman SJ, Estevez M, Magill AB, et al. Case reports showing a long-term effect of subanesthetic ketamine infusion in reducing l-DOPA-Induced dyskinesias. Case Rep Neurol. 2016 Jan;8(1):53–8. doi: 10.1159/000444278
   PubMedGoogle Scholar
• Ballard ED, Zarate CA Jr. The role of dissociation in ketamine’s antidepressant effects. Nat Commun. 2020 Dec 22;11(1):6431.
   PubMed Web of Science ®Google Scholar
• Lanza K, Bishop C. Dopamine D3 receptor plasticity in Parkinson’s disease and L-DOPA-Induced dyskinesia. Biomedicines. 2021 Mar 19;9(3):314.
   PubMed Web of Science ®Google Scholar
• Bryson S. High dose of mesdopetam may ease levodopa-induced dyskinesia: study 2023 [cited 2023 9 Nov]. Available from: https://parkinsonsnewstoday.com/news/mesdopetam-reduces-levodopa-induced-dyskinesia-parkinsons-trial/
   Google Scholar
• Bourque M, Gregoire L, Patel W, et al. AV-101, a pro-drug antagonist at the NMDA receptor glycine site, reduces L-Dopa induced dyskinesias in MPTP monkeys. Cells. 2022 Nov 8;11(22):3530. doi: 10.3390/cells11223530
   PubMed Web of Science ®Google Scholar
• Gelfin E, Kaufman Y, Korn-Lubetzki I, et al. D-serine adjuvant treatment alleviates behavioural and motor symptoms in Parkinson’s disease. Int J Neuropsychopharmacol. 2012 May;15(4):543–9.
   PubMed Web of Science ®Google Scholar
• Erro R, Mencacci NE, Bhatia KP. The emerging role of phosphodiesterases in movement disorders. Mov Disord. 2021 Oct;36(10):2225–2243. doi: 10.1002/mds.28686
   PubMed Web of Science ®Google Scholar
• Huot P, Johnston TH, Koprich JB, et al. The pharmacology of L-DOPA-induced dyskinesia in Parkinson’s disease. Pharmacol Rev. 2013 Jan;65(1):171–222.
   PubMed Web of Science ®Google Scholar
• Frouni I, Huot P. Glutamate modulation for the treatment of levodopa induced dyskinesia: a brief review of the drugs tested in the clinic. Neurodegener Dis Manag. 2022 Aug;12(4):203–214. doi: 10.2217/nmt-2021-0055
   PubMedGoogle Scholar
• Ashby CR Jr., Wang RY. Pharmacological actions of the atypical antipsychotic drug clozapine: a review. The Synapse. 1996 Dec;24(4):349–94. doi: 10.1002/(SICI)1098-2396(199612)24:4<349:AID-SYN5>3.0.CO;2-D
   PubMed Web of Science ®Google Scholar